Get the Stockscreener App
1.46
5.81%
-0.09
After Hours:
1.42
-0.04
-2.74%
Tiziana Life Sciences Ltd stock is traded at $1.46, with a volume of 382.18K.
It is down -5.81% in the last 24 hours and down -13.61% over the past month.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
See More
Previous Close:
$1.55
Open:
$1.51
24h Volume:
382.18K
Relative Volume:
1.10
Market Cap:
$175.50M
Revenue:
-
Net Income/Loss:
$-13.73M
P/E Ratio:
-11.23
EPS:
-0.13
Net Cash Flow:
$-3.92M
1W Performance:
-18.89%
1M Performance:
-13.61%
6M Performance:
-11.52%
1Y Performance:
+47.50%
1-Day Range:
$1.39
$1.60
1-Week Range:
$1.30
$1.82
52-Week Range:
$0.6295
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Name
Tiziana Life Sciences Ltd
Sector
Industry
Phone
-
Address
-
Compare TLSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.46 | 186.32M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Dec-17-18 | Initiated | Laidlaw | Buy |
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s clinical trial - Proactive financial news
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq - The Manila Times
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer's clinical trial - marketscreener.com
TLSA Initiates Phase 2 Trial of Intranasal Foralumab for Alzheimer's Patients - GuruFocus
Tiziana Life Sciences doses first patient in mid-stage Alzheimer’s trial - Proactive financial news
New intranasal antibody trial targets neuroinflammation in early Alzheimer’s - Stock Titan
Tiziana Life Sciences CEO purchases 163,400 shares in open market - Investing.com India
TLSA CEO Bolsters Stake with New Share Acquisition - GuruFocus
Tiziana Life Sciences CEO Increases Stake With Share Purchase - marketscreener.com
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - The Manila Times
Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab - Quiver Quantitative
Tiziana CEO boosts stake with open-market share purchase - Proactive financial news
Tiziana Life Sciences withdraws proposed public offering due to market conditions - Investing.com
Tiziana Life Sciences Rescinds Proposed Public Offering - Nasdaq
TLSA Cancels Planned Public Offering Amid Market Conditions - GuruFocus
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering - The Manila Times
Tiziana Life Sciences announces withdrawal of proposed public offering - marketscreener.com
Tiziana Life Sciences withdraws proposed share offering - Proactive financial news
TLSA Begins Enrollment for Phase 2 Alzheimer's Clinical Trial - GuruFocus
Tiziana Life Sciences (NASDAQ:TLSA) Trading Down 4.4%Here's Why - MarketBeat
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial - Stock Titan
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer’s trial next week - Proactive financial news
Is Tiziana Life Sciences Ltd a good long term investmentLow Beta Stocks & Make Confident Moves With Forecasting Models - earlytimes.in
Tiziana Life Sciences Shares Drop After Company Unveils Plan to Spin Out IL-6 Program - MSN
Will Tiziana Life Sciences Ltd stock deliver shareholder valueInsider Buying & Daily Stock Trend Watchlist - Newser
How Tiziana Life Sciences Ltd stock reacts to job market data2025 Dividend Review & Stepwise Trade Execution Plans - Newser
Is Tiziana Life Sciences Ltd stock near bottom after declineJuly 2025 Selloffs & Precise Swing Trade Alerts - Newser
Will Tiziana Life Sciences Ltd stock attract ESG investorsWeekly Stock Recap & Low Risk Entry Point Guides - Newser
Tiziana Life Sciences Ltd (TLSA) is looking forward to a strong quarter - setenews.com
Is KN Agri Resources Limited Stock a Safe Long Term Investment Data Breakdown - earlytimes.in
Small cap wrap: Tiziana Life Sciences, Gunnison Copper, Blockmate Ventures, Century Lithium… - Proactive financial news
Is Tiziana Life Sciences Ltd stock undervalued vs historical averagesTrade Exit Report & Weekly Stock Breakout Alerts - Newser
Tiziana Life Sciences to Set Up a Publicly Listed Immunology-Focused Spinout Company, Centered on the IL-6 Market - marketscreener.com
Tiziana Life Sciences stock falls after announcing IL-6 asset spinout By Investing.com - Investing.com Nigeria
Tiziana Life Sciences stock falls after announcing IL-6 asset spinout - Investing.com Nigeria
Tiziana Life Sciences plans spinout of IL-6 antibody program - Proactive financial news
Tiziana Life Sciences (TLSA) Plans Spinout to Develop Anti-IL-6 Antibody - GuruFocus
Tiziana Life Sciences Plans to Spin Off IL-6 Antibody Asset Into New Publicly Listed Company - marketscreener.com
Tiziana Life Sciences Plans to Spin Out Asset as Separate Company - marketscreener.com
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company - The Manila Times
Tiziana Life Sciences (Nasdaq: TLSA) to spin out IL-6 asset into new listed company - Stock Titan
Tiziana Life Sciences Ltd (TLSA) -5.03% in After-hours: What’s Driving the Move? - Stocks Telegraph
Take Profit: Why Tiziana Life Sciences Ltd stock appeals to dividend seekersQuarterly Profit Summary & AI Based Trade Execution Alerts - moha.gov.vn
Ready to Jump After Recent Trade: Tiziana Life Sciences Ltd (TLSA) - Setenews
Tiziana Life Sciences Ltd (TLSA) -5.3% in After-hours: Amid Routine Trading Conditions - Stocks Telegraph
Small cap wrap: Tiziana Life Sciences, Pinnacle Silver & Gold, Rainbow Rare Earths... - Proactive Investors
Phase 2 Trial of Tiziana Life Sciences' Foralumab Gains MyMatch Program Inclusion - GuruFocus
Tiziana Life Sciences’ Phase 2 foralumab trial joins Healey ALS MyMatch Program - Proactive financial news
Tiziana Life Sciences' Foralumab Phase 2 Trial for ALS Accepted into ALS MyMatch Program at Mass General Brigham - Quiver Quantitative
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program - The Manila Times
Tiziana Life Sciences Ltd Stock (TLSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):